Literature DB >> 21925138

Tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis.

Franziska Theilig1, Anne Kathrin Enke, Brigitte Scolari, Danny Polzin, Sebastian Bachmann, Robert Koesters.   

Abstract

In many kidney diseases, the original insult primarily involves the glomerulus and may then pass onto the tubulointerstitium. Several hypotheses link glomerular disease to tubular injury; perhaps the foremost hypothesis involves chronic tubular hypoxia. The reported effects of hypoxia and consecutive stabilization of hypoxia-inducible factors (HIFs), however, are controversial. Hypoxia induces interstitial fibrosis but also has beneficial effects on renal disease progression when HIF is activated pharmacologically. To analyze the impact of HIF on tubulointerstitial disease development in primary glomerular disease, transgenic von Hippel Lindau (VHL)-knockout mice were generated and null expression was induced before the onset of autoimmune IgG-mediated anti-glomerular basement membrane glomerulonephritis (GN). Tubular VHL knockout and, thus, local HIF-α stabilization increased renal production of vascular endothelial growth factor, tumor growth factor-β(1), and platelet-derived growth factor-B, resulting in augmented formation of capillaries and interstitial matrix, and conversion of fibroblasts to myofibroblasts. Within the glomerular disease, VHL knockout reduced the glomerular damage and attenuated tubulointerstitial injury. Likewise, proteinuria, plasma urea concentration, and tubulointerstitial matrix were decreased in VHL knockout with GN. These findings shown that tubular HIF-α stabilization in glomerular disease is beneficial for disease outcome. In comparison with VHL knockout alone, GN is a much stronger activator of fibrosis such that stimuli other than hypoxia may be considered important for renal disease progression.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925138      PMCID: PMC3204192          DOI: 10.1016/j.ajpath.2011.07.012

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Stringent doxycycline dependent control of CRE recombinase in vivo.

Authors:  Kai Schönig; Frieder Schwenk; Klaus Rajewsky; Hermann Bujard
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

Review 2.  Von Hippel-Lindau disease: clinical and molecular perspectives.

Authors:  S C Clifford; E R Maher
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

Review 3.  Significance of postglomerular capillaries in the pathogenesis of chronic renal failure.

Authors:  A Bohle; S Mackensen-Haen; M Wehrmann
Journal:  Kidney Blood Press Res       Date:  1996       Impact factor: 2.687

4.  Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function.

Authors:  Duk-Hee Kang; Jeremy Hughes; Marilda Mazzali; George F Schreiner; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2001-07       Impact factor: 10.121

5.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Authors:  Vera Eremina; Manish Sood; Jody Haigh; András Nagy; Ginette Lajoie; Napoleone Ferrara; Hans-Peter Gerber; Yamato Kikkawa; Jeffrey H Miner; Susan E Quaggin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  Intratumoral hypoxia, radiation resistance, and HIF-1.

Authors:  Gregg L Semenza
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

7.  Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension.

Authors:  H M Lafferty; D L Garcia; H G Rennke; J L Troy; S Anderson; B M Brenner
Journal:  J Am Soc Nephrol       Date:  1991-04       Impact factor: 10.121

8.  Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys.

Authors:  Christian Rosenberger; Stefano Mandriota; Jan Steffen Jürgensen; Michael S Wiesener; Jan H Hörstrup; Ulrich Frei; Peter J Ratcliffe; Patrick H Maxwell; Sebastian Bachmann; Kai-Uwe Eckardt
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

9.  A novel mechanism of nephron loss in a murine model of crescentic glomerulonephritis.

Authors:  Michel Le Hir; Valérie Besse-Eschmann
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

10.  Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.

Authors:  Cheng-Jun Hu; Li-Yi Wang; Lewis A Chodosh; Brian Keith; M Celeste Simon
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

View more
  14 in total

Review 1.  Impaired hypoxia-inducible factor (HIF) regulation by hyperglycemia.

Authors:  Sergiu-Bogdan Catrina
Journal:  J Mol Med (Berl)       Date:  2014-06-12       Impact factor: 4.599

Review 2.  How tubular epithelial cells dictate the rate of renal fibrogenesis?

Authors:  Kevin Louis; Alexandre Hertig
Journal:  World J Nephrol       Date:  2015-07-06

3.  Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney.

Authors:  Henrik Dimke; Matthew A Sparks; Benjamin R Thomson; Sebastian Frische; Thomas M Coffman; Susan E Quaggin
Journal:  J Am Soc Nephrol       Date:  2014-11-10       Impact factor: 10.121

Review 4.  Hypoxia and Dysregulated Angiogenesis in Kidney Disease.

Authors:  Shinji Tanaka; Tetsuhiro Tanaka; Masaomi Nangaku
Journal:  Kidney Dis (Basel)       Date:  2015-04-15

5.  Inflammatory cells of immunosuppressive phenotypes in oral lichen planus have a proinflammatory pattern of expression and are associated with clinical parameters.

Authors:  Marilena Vered; Eran Fürth; Yifat Shalev; Dan Dayan
Journal:  Clin Oral Investig       Date:  2012-08-15       Impact factor: 3.573

Review 6.  Hypoxia-Inducible Factor and Oxygen Biology in the Kidney.

Authors:  Mai Sugahara; Tetsuhiro Tanaka; Masaomi Nangaku
Journal:  Kidney360       Date:  2020-07-22

7.  Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

Authors:  Vera Ivanova; Olga B Garbuzenko; Kenneth R Reuhl; David C Reimer; Vitaly P Pozharov; Tamara Minko
Journal:  Eur J Pharm Biopharm       Date:  2012-12-08       Impact factor: 5.571

8.  Central role for endothelial human deneddylase-1/SENP8 in fine-tuning the vascular inflammatory response.

Authors:  Stefan F Ehrentraut; Douglas J Kominsky; Louise E Glover; Eric L Campbell; Caleb J Kelly; Brittelle E Bowers; Amanda J Bayless; Sean P Colgan
Journal:  J Immunol       Date:  2012-12-03       Impact factor: 5.422

9.  Deletion of von Hippel-Lindau protein converts renin-producing cells into erythropoietin-producing cells.

Authors:  Birguel Kurt; Alexander Paliege; Carsten Willam; Ilona Schwarzensteiner; Kathrin Schucht; Hanna Neymeyer; Maria Luisa S Sequeira-Lopez; Sebastian Bachmann; R Ariel Gomez; Kai-Uwe Eckardt; Armin Kurtz
Journal:  J Am Soc Nephrol       Date:  2013-02-07       Impact factor: 10.121

10.  Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts.

Authors:  Ruth E Schietke; Thomas Hackenbeck; Maxine Tran; Regina Günther; Bernd Klanke; Christina L Warnecke; Karl X Knaup; Deepa Shukla; Christian Rosenberger; Robert Koesters; Sebastian Bachmann; Peter Betz; Gunnar Schley; Johannes Schödel; Carsten Willam; Thomas Winkler; Kerstin Amann; Kai-Uwe Eckardt; Patrick Maxwell; Michael S Wiesener
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.